Celgene Corp said on Tuesday that in a late-stage clinical trial, patients with metastatic melanoma who took its drug Abraxane lived for a longer period without getting worse than those who received the chemotherapy dacarbazine.
ShareSaturday, November 3, 2012
Friday, November 2, 2012
Resistance In Melanoma Patients Delayed By Combination Of Targeted Treatment Drugs
Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma .
Share
Skin Cancer
Combination,
Delayed,
drugs,
Melanoma,
Patients,
Resistance,
Targeted,
treatment
Subscribe to:
Posts (Atom)
